Complement-mediated alteration of antibody specificity in vivo

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Antibody-mediated tumor targeting is a key immunotherapy strategy.
• The role of complement in modulating antibody efficacy in vivo requires further elucidation.

Purpose of the Study:

• To investigate the effect of complement on the in vivo pharmacokinetics and specificity of anti-tumor antibodies.
• To determine if complement enhances the clearance of anti-tumor antibodies through non-specific mechanisms.

Main Methods:

• Simultaneous injection of heterologous anti-EL4 lymphoma serum and complement into non-tumor bearing mice.
• Comparison of antibody titers in the presence and absence of functional complement.
• Assessment of complement's effect on clearance of anti-tetanus toxin serum.
• In vivo studies in guinea pig tumor models.

Main Results:

• Complement significantly enhanced the rapid disappearance of anti-EL4 lymphoma antibody from circulation.
• This enhancement was dependent on a complement source capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC).
• Complement did not affect the clearance of anti-tetanus toxin serum, indicating a specific interaction with anti-tumor antibodies.
• Complement also altered the specificity of anti-tumor antibodies in vivo, suggesting increased avidity for cross-reactive determinants.

Conclusions:

• Functional complement plays a critical role in enhancing the in vivo clearance and specificity of anti-tumor antibodies.
• Complement-mediated enhancement of anti-tumor antibody absorption is not due to general clearance of foreign gamma-globulin.
• These findings suggest that complement can augment the therapeutic potential of antibody-based cancer treatments by refining antibody specificity.